1.Acute kidney injury in the patient with cancer
Mitchell H ROSNER ; Mark A PERAZELLA
Kidney Research and Clinical Practice 2019;38(3):295-308
Dramatic advances in the care of patients with cancer have led to significant improvement in outcomes and survival. However, renal manifestations of the underlying cancer as well as the effects of anti-neoplastic therapies leave patients with significant morbidity and chronic kidney disease risks. The most common renal manifestations associated with cancer include acute kidney injury (AKI) in the setting of multiple myeloma, tumor lysis syndrome, post-hematopoietic stem cell therapy, and AKI associated with chemotherapy. Knowledge of specific risk factors, modification of risk and careful attention to rapid AKI diagnosis are critical for improving outcomes.
Acute Kidney Injury
;
Diagnosis
;
Drug Therapy
;
Humans
;
Multiple Myeloma
;
Renal Insufficiency, Chronic
;
Risk Factors
;
Stem Cells
;
Tumor Lysis Syndrome
2.Clinical analysis of 18 cases with acute tumor lysis syndrome in children with B-cell lymphoma.
Shuang HUANG ; Jing YANG ; Rui ZHANG ; Yan-long DUAN ; Yong-hong ZHANG
Chinese Journal of Pediatrics 2011;49(8):622-625
OBJECTIVETo investigate risk factors associated with acute tumor lysis syndrome (ATLS) in children with B-cell lymphoma and to explore feasible means for the prophylaxis and treatment.
METHODData from 18 children with ATLS in B-cell lymphoma were collected to assess their tumor burden at diagnosis and before chemotherapy. Evaluation was performed at the 8th day, 3 month, and the end of chemotherapy and follow up. The incidence of ATLS in B-cell lymphoma, and the relationship between the incidence of ATLS and whether the kidney was involved and large tumor burden were analyzed respectively. All patients received hydration, alkalinization and received allopurinol routinely. Urate oxidase and hemodialysis treatment were administered in some cases.
RESULTOf the 103 children with B-cell lymphoma, 18 were diagnosed as having ATLS (17.5%). All the 18 cases with ATLS were histopathologically confirmed as having Burkitt's lymphoma. All the patients were at stage III or IV and all had large tumor sizes, and 7 were found to have blasts in the bone marrow>25% (38.9%). Lactate dehydrogenase (LDH) levels≥1000 U/L were found in 11 (61.1%) cases. All patients had developed metabolic abnormalities, including hyperuricemia, hyperphosphatemia, hypocalcemia, and uremia. In terms of clinical features and prognosis, all cases had nausea, vomiting, anorexia, oliguria, and anuria at different levels. One had gastrointestinal bleeding, 7 patients experienced seizures. The etiology in five was hypocalcemia and two had reversible posterior encephalopathy syndrome and all responded well to treatment. Nine cases of ATLS responded to supportive care, 4 required hemodialysis, and the other 4 responded to urate oxidase. Ten cases survived and 8 died. The major cause of death was severe complications and treatment was given up in 5 cases and recurrence occurred in 3 cases.
CONCLUSIONATLS was commonly seen in Burkitt's subtype of B-cell lymphoma. Higher LDH and large tumor sizes and kidney involvement were important risk factors for the development of ATLS in children with B-cell lymphoma. Treatments with hydration, alkalinization and allopurinol were safe and effective. Urate oxidase and hemodialytic treatments should be given timely.
Child ; Humans ; Kidney ; physiopathology ; L-Lactate Dehydrogenase ; analysis ; Lymphoma, B-Cell ; complications ; diagnosis ; drug therapy ; Risk Factors ; Tumor Burden ; Tumor Lysis Syndrome ; diagnosis ; drug therapy ; etiology
3.Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient.
Jin Ok KIM ; Dae Won JUN ; Hye Jin TAE ; Kang Nyeong LEE ; Hang Lak LEE ; Oh Young LEE ; Ho Soon CHOI ; Byung Chul YOON ; Joon Soo HAHM
Clinical and Molecular Hepatology 2015;21(1):85-88
Tumor lysis syndrome is rare in hepatocellular carcinoma (HCC), but it has been reported more frequently recently in response to treatments such as transcatheter arterial chemoembolization (TACE), radiofrequency thermal ablation (RFTA), and sorafenib. Tumor lysis syndrome induced by low-dose steroid appears to be very unusual in HCC. We report a patient with hepatitis-C-related liver cirrhosis and HCC in whom tumor lysis syndrome occurred due to low-dose steroid (10 mg of prednisolone). The patient was a 90-year-old male who presented at the emergency room of our hospital with general weakness and poor oral intake. He had started to take prednisolone to treat adrenal insufficiency 2 days previously. Laboratory results revealed hyperuricemia, hyperphosphatemia, and increased creatinine. These abnormalities fulfilled the criteria in the Cairo-Bishop definition of tumor lysis syndrome. Although the patient received adequate hydration, severe metabolic acidosis and acute kidney injury progressed unabated. He finally developed multiple organ failure, and died 3 days after admission. This was a case of tumor lysis syndrome caused by administration of low-dose steroid in a patient with HCC.
Acute Kidney Injury/pathology
;
Aged, 80 and over
;
Antineoplastic Agents/therapeutic use
;
Carcinoma, Hepatocellular/*pathology/therapy
;
Chemoembolization, Therapeutic
;
Creatinine/blood
;
Humans
;
Liver Neoplasms/*pathology/*therapy
;
Male
;
Niacinamide/analogs & derivatives/therapeutic use
;
Phenylurea Compounds/therapeutic use
;
Steroids/adverse effects/therapeutic use
;
Tomography, X-Ray Computed
;
Tumor Lysis Syndrome/*diagnosis/drug therapy